

Comments Submitted by Otsuka Pharmaceutical Co. Ltd., Japan

File Name / Type	The Purpose for Submission
Supplemental / Additional Data Supporting Otsuka Protocols	
Otsuka1.pdf (Table 7-1) Prepared & Updated April 2002	Available IC50 Values for Substances Tested for Antagonism Activity in <i>in-vitro</i> AR TA Assay
Otsuka2.pdf	Establishment of “CHO-LUC cell” which has constitutive expression of luciferase for cell toxicity evaluation. <i>(Supplemental /Alternative Protocol for Monitoring the Cell Toxicity with Stable CHO-LUC Cell Lines by Otsuka).</i>
Corrections Submitted by Otsuka Pharmaceutical Co. Ltd., Japan in BRDs	
Otsuka3.pdf (April 2002)	Table 1: ER TA Reporter Gene assay Using Various Mammalian cells Table 2: ERTA Reporter Gene Assays Using Mammalian Cells
Otsuka4.pdf (Draft AR TA BRD –Appendix E1)	Table: Substances Tested for Agonism Activity
Otsuka5.pdf (Draft AR TA BRD –Section 2, Table 2-1)	Cell Lines, Plasmids, and Reference Androgen Values Used in <i>in-vitro</i> AR TA Assays
Otsuka6.pdf (Draft AR TA BRD –Appendix E-2, Table)	Substances Tested for Antagonism Activity